Literature DB >> 26309109

Attenuation of the pressor response to exogenous angiotensin by angiotensin receptor blockers and benazepril hydrochloride in clinically normal cats.

Tiffany L Jenkins, Amanda E Coleman, Chad W Schmiedt, Scott A Brown.   

Abstract

OBJECTIVE: To compare the attenuation of the angiotensin I-induced blood pressure response by once-daily oral administration of various doses of angiotensin receptor blockers (irbesartan, telmisartan, and losartan), benazepril hydrochloride, or lactose monohydrate (placebo) for 8 days in clinically normal cats. ANIMALS: 6 healthy cats (approx 17 months old) with surgically implanted arterial telemetric blood pressure-measuring catheters. PROCEDURES: Cats were administered orally the placebo or each of the drug treatments (benazepril [2.5 mg/cat], irbesartan [6 and 10 mg/kg], telmisartan [0.5, 1, and 3 mg/kg], and losartan [2.5 mg/kg]) once daily for 8 days in a crossover study. Approximately 90 minutes after capsule administration on day 8, each cat was anesthetized and arterial blood pressure measurements were recorded before and after IV administration of each of 4 boluses of angiotensin I (20, 100, 500, and 1,000 ng/kg). This protocol was repeated 24 hours after benazepril treatment and telmisartan (3 mg/kg) treatment. Differences in the angiotensin I-induced change in systolic arterial blood pressure (ΔSBP) among treatments were determined.
RESULTS: At 90 minutes after capsule administration, only losartan did not significantly reduce ΔSBP in response to the 3 higher angiotensin doses, compared with placebo. Among drug treatments, telmisartan (3 mg/kg dosage) attenuated ΔSBP to a significantly greater degree than benazepril and all other treatments. At 24 hours, telmisartan was more effective than benazepril (mean ± SEM ΔSBP, 15.7 ± 1.9 mm Hg vs 55.9 ± 12.42 mm Hg, respectively). CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated that telmisartan administration may have advantages over benazepril administration for cats with renal or cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26309109     DOI: 10.2460/ajvr.76.9.807

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

Review 1.  The renin-angiotensin-aldosterone system and its suppression.

Authors:  Marisa K Ames; Clarke E Atkins; Bertram Pitt
Journal:  J Vet Intern Med       Date:  2019-02-26       Impact factor: 3.333

2.  Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial.

Authors:  Amanda E Coleman; Scott A Brown; Anne M Traas; Lawrence Bryson; Tanja Zimmering; Alicia Zimmerman
Journal:  J Vet Intern Med       Date:  2019-03-09       Impact factor: 3.333

3.  Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial.

Authors:  Tony M Glaus; Jonathan Elliott; Esther Herberich; Tanja Zimmering; Balazs Albrecht
Journal:  J Vet Intern Med       Date:  2018-12-18       Impact factor: 3.333

4.  Comparison of Doppler ultrasonic and oscillometric devices (with or without proprietary optimisations) for non-invasive blood pressure measurement in conscious cats.

Authors:  Petra Cerna; Panos E Archontakis; Hester Ok Cheuk; Danièlle A Gunn-Moore
Journal:  J Feline Med Surg       Date:  2020-06-25       Impact factor: 2.015

Review 5.  Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease.

Authors:  Francesca De Santis; Andrea Boari; Francesco Dondi; Paolo Emidio Crisi
Journal:  Animals (Basel)       Date:  2022-01-21       Impact factor: 2.752

6.  ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats.

Authors:  Mark J Acierno; Scott Brown; Amanda E Coleman; Rosanne E Jepson; Mark Papich; Rebecca L Stepien; Harriet M Syme
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.